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Abstract
Three educational interventions were simulated in a system dynamics model of the medical use,
trafficking, and nonmedical use of pharmaceutical opioids. The study relied on secondary data
obtained in the literature for the period of 1995 to 2008 as well as expert panel recommendations
regarding model parameters and structure. The behavior of the resulting systems-level model was
tested for fit against reference behavior data. After the base model was tested, logic to represent
three educational interventions was added and the impact of each intervention on simulated
overdose deaths was evaluated over a 7-year evaluation period, 2008 to 2015. Principal findings
were that a prescriber education intervention not only reduced total overdose deaths in the model
but also reduced the total number of persons who receive opioid analgesic therapy, medical user
education not only reduced overdose deaths among medical users but also resulted in increased
deaths from nonmedical use, and a “popularity” intervention sharply reduced overdose deaths
among nonmedical users while having no effect on medical use. System dynamics modeling
shows promise for evaluating potential interventions to ameliorate the adverse outcomes
associated with the complex system surrounding the use of opioid analgesics to treat pain.

Keywords
alcohol and substance abuse; dynamic modeling; modeling and simulation; nonlinear dynamics;
substance use; systems science

© 2013 Society for Public Health Education
Corresponding Author: Alexandra Nielsen, Portland State University, PO Box 751, Portland, OR 97207-0751, USA.
alexan3@pdx.edu.
Declaration of Conflicting Interests
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this
article: In the 12 months prior to May 1, 2013, Lynn Webster has served either as a consultant, on the advisory board, or has received
honoraria from the following organizations: AstraZeneca, Covidien Mallinckrodt, CVS, Jazz Pharmaceuticals, Medtronic, Nektar
Therapeutics, Neura Therapeutics, and Theravance. No formal restrictions were placed on research or communication of findings;
however, prior to submission for publication, the manuscript was reviewed by a Purdue Pharma L.P. review committee, and minor
nonsubstantive changes were made to the manuscript to improve flow and sharpen the vocabulary.

Wakeland et al.

Page 2

A dramatic rise in the nonmedical use of pharmaceutical opioids has presented the United
States with a substantial public health problem (Compton & Volkow, 2006). Despite the
increasing prevalence of negative outcomes, such as fatal and nonfatal overdoses,
nonmedical use of pharmaceutical opioids remains largely unabated by current policies and
regulations (Fishman, Papazian, Gonzalez, Riches, & Gilson, 2004). Resistance to policy
interventions likely stems from the complexity of the medical and nonmedical use of
pharmaceutical opioids, as interactions among prescribers, pharmacists, persons obtaining
opioids for medical or nonmedical use, opioid traffickers, and public health advocates result
in chains of causal relationships and instances of information feedback in the system.
This article presents a system dynamics (SD) model of the U.S. opioid-related complex
system. This model is designed to foster a more complete understanding of how medical
use, trafficking, and nonmedical use are interrelated, and to identify points of high leverage
for educational interventions on the epidemic of nonmedical use. Three potential
interventions are simulated, relative costs and benefits are estimated, and possible
counterintuitive downstream effects are high-lighted. The term opioids is used to mean
pharmaceutically manufactured opioid (morphine-like) medicines, most of which are
indicated for use as analgesics, and does not include heroin or other illicit opioid drug
substances.

Background
The number of U.S. unintentional fatal poisonings involving opioid analgesics tripled
between 1999 and 2006 (Warner, Chen, Makuc, Anderson, & Miniño, 2011; see Figure 1),
increasing more than fivefold among those aged 15 to 24 years (Warner, Chen, & Makuc,
2009). Diversion of opioids is assumed to be a major source of supply for nonmedical use.
Among those survey respondents to the 2010-2011 National Surveys of Drug Use and
Health (NSDUH) who received opioids for free from friends or relatives, about 82%
reported that their source had originally received the drugs from one doctor (Substance
Abuse and Mental Health Services Administration [SAMHSA], 2012). Recent increases in
opioid prescribing stem in part from increases in the diagnosis and recognition of the need to
treat chronic noncancer pain. Data from NHANES (Hardt, Jacobsen, Goldberg, Nickel, &
Buchwald, 2008) support an estimate of 29 million Americans aged 20 years or older with
chronic pain in the period 1999-2002. Opioid treatment for chronic, noncancer pain is not
without controversy (Collett, 2001), but opioids have been found to be more effective at
ameliorating pain than alternative medications (see Furlan, Sandoval, Mailis-Gagnon, &
Tunks, 2006, for a review), and their prescription and medical use have become increasingly
common over the last decade (Governale, 2007, 2008a, 2008b).
In July 2012, the Food and Drug Administration (FDA) approved a shared Risk Evaluation
and Mitigation Strategy (REMS) for all Extended-Release and Long-Acting (herein-after
“long-acting”) opioid analgesics (FDA, 2012). Unfortunately, nonmedical use of
pharmaceutical opioids has tended to resist policy and regulation (Fishman et al., 2004), and
the effectiveness of many REMS interventions (e.g., medication guides and prescriber
training) remains inconclusive at this time (see Chou, Ballantyne, Fanciullo, Fine, &
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Miaskowski, 2009, for a review). Tools are needed to assess intervention alternatives for
their capacity to balance the benefits and risks of opioids in the United States. Policy
makers, striving to ameliorate the adverse outcomes associated with opioid analgesics, could
benefit from a systemslevel model that reflects the complexity of the system and that
incorporates the full range of available data.

An SD Simulation Model
The current work features an SD simulation model that represents the fundamental dynamics
of opioids as they are prescribed, unlawfully trafficked, used nonmedically, and involved in
overdose mortality. SD modeling uses a set of differential equations that are integrated
numerically to simulate system behavior over time. This allows researchers to incorporate
information on various factors into a single model that represents behaviors at a system
level.
SD models have been successfully applied to analysis of a number of public health issues,
including tobacco (Cavana & Tobias, 2008), cocaine (Homer, 1993), diabetes treatment
(Jones et al., 2006), and health care reform (Milstein, Homer, & Hirsch, 2010). The
approach is well-suited to health policy analyses involving complex chains of influence
(Sterman, 2006), as these often involve feedback loops and nonlinear relationships that are
beyond the capabilities of statistical models. The approach is especially useful for
identifying points of leverage for intervention and for indicating potential negative
consequences of those interventions (Sterman, 2000). This provides policy makers with
information that is not available from research focused on individual aspects of a system
(Sterman, 2006).
The current SD model was developed over a 2-year period through collaborative efforts of a
modeling team and a panel of experts in policy and the use/abuse of opioid analgesics. This
model complements and leverages results from an extensive amount of research on the use
and abuse of pharmaceutical opioids in the United States. Much of the current body of
knowledge regarding the interrelated public health problems of medical and nonmedical use
of opioid analgesics is based on surveys and inferential statistics. Because of limitations of
the surveys and differences in their methods, caution is required when defining populations
of interest and relationships between variables, especially variables that are similar but not
exactly the same across surveys. Guidance was often provided by the expert panel in
reconciling apparent differences between sources and making assumptions about how causal
relationships would be best represented in the model.
Dynamics of the Opioid System
The system model estimates overdose fatalities in which opioid analgesics were involved
based on the dynamics of medical treatment with opioids, initiation and prevalence of
nonmedical usage, and drug trafficking supply and demand. Discussion of each sector
includes a table of empirical support, a narrative of the model’s behavior, and a diagram
depicting model structure. Verbal descriptions contain bracketed numbers that correspond to
specific points in the diagrams. The model contains 40 parameters, 41 auxiliary variables,
and 7 state variables, as well as their associated equations and graphical functions.
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Medical Use Sector
Diagnostic criteria from DSM-IV have been used to differentiate persons who engage in
problematic substance use according to whether or not they meet the mutually exclusive
specific criteria for either opioid abuse or opioid dependence—the latter referred to by many
as addiction (American Psychiatric Association, 1994). Historically, increases in opioid
abuse and addiction have led to the implementation of regulatory policies for opioids (FDA,
2008). These have been shown to lead many physicians to avoid prescribing opioids out of
fear of overzealous regulatory scrutiny (Joranson, Gilson, Dahl, & Haddox, 2002) and may
also lead them to decrease the amount of opioids they prescribe, limit quantities and refills,
and shift prescribing to opioid analgesic drug products with a presumably lower risk of
abuse, addiction, or overdose (Wolfert, Gilson, Dahl & Cleary, 2010). Specifically,
physicians have been found to exhibit more caution in prescribing long-acting opioid
analgesics (Potter et al., 2001), due to greater concerns about the development of physical
dependence, tolerance, and addiction, and because most of them are classified in the most
restrictive schedule defined in the federal Controlled Substances Act. (See Table 1 for
additional empirical support for the medical use sector.)
As illustrated in Figure 2, the system model assumes that a proportion of the U.S. population
is diagnosed with a chronic pain condition each year {1}. A fraction of these people are
subsequently treated with either short-acting {2} or long-acting {3} opioid formulations, and
become members of one of the populations of patients under opioid treatment ostensibly for
chronic pain. Patients who begin treatment with short-acting formulations may cease
treatment if their condition improves, or some may switch to long-acting formulations if
their pain conditions appear to worsen {4}.
Each year some individuals move from the stocks of “individuals receiving opioids” {2-3}
to the stocks of “individuals receiving opioids with abuse or addiction” {5-6}. The fraction
of individuals with abuse or addiction {7} influences physicians’ perception of the risk
involved in opioid prescribing {8}, as does the total number of accidental overdose deaths
involving opioid analgesics among medical users each year {9}. As physicians perceive
higher levels of risk {8} they become increasingly biased toward prescribing short-acting
formulations {10}, and their overall rates of opioid prescribing decrease {11}. This response
slows the amount of abuse, addiction, and overdoses {7}, which tends to stabilize the
medical use sector of the model.
Trafficking Sector
Findings from Manchikanti et al. (2006) indicate that 5% of chronic pain patients engage in
doctor shopping and around 4% engage in forgery. (See Table 2 for additional empirical
support.) As shown in Figure 3, a fixed proportion of the persons with abuse or addiction are
assumed to engage in trafficking each year, including doctor shopping {1} and forgery {2}
of prescriptions for long-acting and/or short-acting medications. The number of extra
prescriptions acquired {3} is assumed to be a product of the total number of individuals
engaging in trafficking and the number of extra prescriptions obtained per trafficker {11}.
Some proportion of these excess prescriptions is assumed to be kept by the traffickers
themselves rather than transferred to others {4}. The amount kept for personal use is a
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product of the number of traffickers with abuse or addiction and the average number of extra
prescriptions used per year by them. The number of prescriptions used by the trafficker is
then subtracted from the number of extra prescriptions acquired. The remainder is converted
to dosage units {5}, representing opioid drug products dispensed from pharmacies from the
fraudulently obtained prescriptions, and diverted to nonmedical users {6}.
Trafficked opioids accumulate in a stock of dosage units {7} that are consumed according to
demand from the nonmedical use sector. The “months of supply available” {8} indicates the
extent to which the trafficked supply is able to meet the trafficking-oriented demand. When
the trafficked supply of opioids becomes limited, an increased profit motive emerges {9}
and motivation to forge prescriptions and doctor shop increases. When supply is large
compared with demand, the opposite is true. As this motivation fluctuates, the number of
extra prescriptions each trafficker would like to obtain {10} also changes. But the number of
trafficked prescriptions that can be successfully redeemed for opioid drug products is
attenuated by cautious dispensing when perceived risk is high among physicians and
pharmacies {11}, which tends to stabilize the amount of trafficking.
Nonmedical Use Sector
Around 12% to 14% of individuals who use opioids nonmedically meet the criteria for abuse
or dependence (Colliver, Kroutil Dai, & Gfroerer, 2006), and statistical analysis of the full
NSDUH (2009) data set indicated that respondents with abuse or dependence reported a
median frequency of opioid usage during the past year 38 times greater than respondents
without abuse or dependence. Extrapolation from heroin findings indicates that higherfrequency opioid use is associated with a significantly higher all-cause mortality rate (WHO;
see Degenhardt, Hall, Warner-Smith, & Lynskey, 2004; Hser, Hoffman, Grella, & Anglis,
2001) and supports a distinction between two subpopulations of nonmedical users (low and
high frequency) in this sector of the model. (See Table 3 for additional empirical support for
this sector.)
As illustrated in Figure 4, within the model a percentage of the U.S. population {1} initiates
nonmedical use each year {2}, all of whom start out in a stock of “low-frequency
nonmedical users,” and a small percentage of whom then advance to a stock of “highfrequency nonmedical users” {3} during each subsequent year. The total number of
individuals using opioids nonmedically {4} is divided by the current number of individuals
in the United States who are using other drugs nonmedically {5} to calculate the relative
popularity of opioids for nonmedical use {6}. As the popularity of using opioids
nonmedically increases, the rate of initiation increases, creating a positive feedback loop that
acting on its own would result in an exponential increase in the rate of initiation.
Nonmedically used opioids are obtained through a variety of routes, but of chief interest for
the current research is the prevalence of opioid “trafficking” (i.e., buying or selling) via
persons who are receiving these products ostensibly for treatment. Results from the 2006
NSDUH survey (SAMHSA, 2007) indicate that 75% of the nonmedical demand for opioids
is met via interpersonal sharing or theft from friends or relatives. The remaining 25%
represents the demand met by trafficking {8}. The focus on trafficking in the model reflects
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the emphasis in the medical sector on prescribing for chronic pain, and the assumption that
chronic pain medicines are less likely to be left over or shared.
In the model, demand for opioids (long- and short-acting) is calculated from the number of
individuals in low- and high-frequency populations {7}. When the trafficking supply {8} is
ample relative to demand, the rate of initiation {2} and the rate of advancement from lowfrequency to high-frequency use {3} is somewhat enhanced. However, when the 25% of
opioids for nonmedical use supplied by trafficking is limited (or even negative), rates of
initiation and advancement decrease appreciably. The ratio of supply to demand {9}
indicates the degree to which opioids are accessible for nonmedical use. As the populations
of nonmedical users increase beyond what trafficking can support, accessibility becomes
limited. This decreases initiation and advancement and this balancing loop offsets the
exponential increase in nonmedical use driven by the popularity feedback loop.

Model Testing
The model was tested in detail to determine its robustness and ability to endogenously match
simulated data against historical data (refer to Sterman, 2000, for a list of standard tests for
confidence). Model outputs were compared with reference data for the historical period
(1995 to 2008) where these data were available, as shown in Figure 5. Overall, simulated
results were consistent with the empirical reference data despite the complex patterns
exhibited, and baseline results were considered sufficiently plausible to proceed with
exploratory analysis.

Results
To illustrate the potential for evaluating interventions, logic representing three possible
interventions was added to the model to calculate their relative potential impacts on the
number of opioid overdose deaths in the United States. The model was run over a time
period of 20 years, which was divided into a historical period—1995 to 2008—and an
evaluation period—2008 to 2015. All interventions were represented as simple toggles, with
exaggerated impacts that demonstrate the model’s relative response at multiple points of
leverage.
Prescriber Intervention
The implementation of a prescriber education program was simulated by doubling prescriber
perception of risk and reducing rates of addiction by half. Given a simulated education
intervention, prescribers perceived opioid prescribing as twice as risky and were twice as
effective in monitoring patients for signs of abuse. The increased risk caused prescribers to
treat half as many chronic pain patients with opioids and to be doubly biased toward
prescribing short-acting formulations. Their increased effectiveness in monitoring treatment
also resulted in a 50% reduction in the number of patients who developed abuse or
addiction.
The prescriber intervention simulation caused a marked decrease in the number of overdose
deaths among medical users in the model (see Figure 6B), as wary prescribers offered opioid
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therapy to fewer individuals. Nonmedical overdose deaths also decreased, as there were
fewer individuals with abuse or addiction who could engage in trafficking and increased
difficulty in obtaining fraudulent prescriptions. Constraining the trafficked supply reduced
the number of nonmedical users and nonmedical overdose deaths. However, this
intervention also resulted in a denial of therapeutic treatment to individuals with legitimate
chronic pain complaints.
Medical User Intervention
This intervention simulated a patient-level education program that halved the rate at which
medical users with chronic pain developed abuse or addiction. In contrast to the prescriber
intervention, this simulation maintained the baseline level of prescriber risk perception. Not
surprisingly, this caused a decrease in the number of medical user deaths (see Figure 6C).
However, because the number of deaths among nonmedical users continued to grow, the
reduction in deaths among medical users was not enough to prevent an overall increasing
trend in overdose deaths in the model.
The increasing trend in the number of nonmedical users stemmed from the vicious cycle of
opioid popularity. An immediate cut in the fraction of individuals developing opioid abuse
or addiction caused the perception of opioid risk to drop. In a climate of lower risk,
prescribers became less cautious and prescriptions were easier to obtain by fraudulent
means. This small rise in fraudulent supply available through traffickers permitted a slight
increase in the number of nonmedical users. And because of the self-reinforcing nature of
the popularity feedback loop, this slight increase led to a noticeable increase in nonmedical
use and overdose deaths in the nonmedical sector.
Popularity Intervention
The popularity intervention simulated an education program targeted at nonmedical users
that halved the rate of initiation and also the level of perceived popularity of opioids for
nonmedical use. Sharply reducing initiation and perceived popularity caused a substantial
reduction in the number of overdose deaths in the model (see Figure 6D). Once the user
populations declined, the self-reinforcing nature of popularity worked in a virtuous cycle of
decreased use and decreased popularity. This further reduced rates of nonmedical use and
overdose deaths in the nonmedical use sector.
Discussion
Results indicate that SD modeling holds promise as a tool for understanding the phenomena
contributing to the nonmedical use of opioids and for evaluating the potential impact of
educational interventions on the epidemic of overdose deaths in which pharmaceutical
opioids are reported. By deliberately exaggerating the direct effects of three potential
options, downstream effects were accentuated to allow for direct comparison of alternatives
and to make obvious any possible unintended consequences or counterintuitive results.
Results of the interventions suggest that prescriber-level education initiatives, such as
promotion of careful screenings of patients who receive opioid therapy (Fishbain et al.,
2008), may be a more effective way to reduce abuse, addiction, and unintentional overdose
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deaths than patient-level education initiatives. Surprisingly, reducing the rate of abuse or
addiction among medical users resulted in more overdose deaths, because, in the model,
lower rates of abuse and addiction led to lower perception of risk among prescribers, more
prescribing, and ultimately more trafficking to nonmedical users.
However, restrictions at the prescriber level suggest that more chronic pain sufferers would
also be denied potentially beneficial therapy. By intervening at the level of the medical user,
the number of overdose deaths decreased in the medical sector without denying any
additional patients treatment. It is possible that a medical user intervention could be
amplified with additional efforts to reduce diversion to the nonmedical sector, but among the
interventions tested in this study, it appears that patient education interventions may be less
effective at reducing overdose deaths in the United States.
The popularity intervention, which directly targeted the nonmedical use sector, was found to
be the most powerful point of leverage in reducing deaths among nonmedical users; and
research indicates that more than half of opioid overdose deaths are suffered by individuals
who have never been prescribed opioids directly (Hall et al., 2008). This intervention would
likely have the greatest impact on adolescents and young adults, populations with the
greatest rates of nonmedical use (SAMHSA, 2012). However, it is also important to
consider the distal impacts of interventions in the medical sector on the nonmedical sector.
The prescriber intervention indirectly limited the supply of opioids available for nonmedical
use and resulted in the largest reduction in overdose deaths among the three interventions
compared.
Limitations
Despite great efforts to find empirical support for all model parameters, parameter validity
remains a primary limitation in the study (Wakeland et al., 2010). Several parameters have
weak empirical support, and a number of potentially important factors have been excluded,
often because evidence to support them remains elusive. For example, the trafficking sector
focuses solely on trafficking as a mode of diversion, even though a large fraction of
nonmedical use demand is met by interpersonal sharing among friends and relatives. There
is very limited empirical evidence on interpersonal sharing, but because of its importance
this mechanism would ideally be included in a more detailed fashion. Additional detail on
opioid trafficking would also be ideal, as it is currently assumed that only individuals with
chronic pain who also abuse or are addicted to opioids engage in trafficking, and that the
number of traffickers is stable with changes in supply and demand. There are no reliable
data on how many individuals masquerade as pain patients so as to acquire medicine for
illicit resale, but anecdotally, some individuals are merely engaged in a criminal enterprise
and have no interest in abusing the drugs they buy and sell.
Some additional boundary exclusions include polydrug use and abuse, and the use of
substitute substances such as heroin. Without modeling the larger system of nonmedical and
illicit use of substances, we are not able to explore the impact of drug switching or polydrug
abuse on unintentional overdose deaths in the United States. Opioid treatment programs,
alternative treatments, and secular factors—such as payer policies and formularies—are also
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likely to influence rates of medical and nonmedical use of opioids and the outcomes
associated with such use, but were not included in the current model.
Finally, the model focuses exclusively on prescribing and diversion of opioids for the
treatment of chronic noncancer pain, without representing the vastly larger number of
persons who receive them for acute pain. Chronic pain was of primary interest in the current
model because policy interventions that restrict opioid prescribing may have an especially
large impact on individuals with long-term pain conditions. However, a larger fraction of the
opioids dispensed annually are prescribed to treat acute pain conditions and contribute to the
supply of opioids for nonmedical use as well as to physicians’ perception of risk in
prescribing.

Conclusion
Work is underway to address many of the above limitations, but limitations notwithstanding,
the present study serves well to demonstrate how a systems-level model can inform
interventions on the nonmedical use of pharmaceutical opioids. It is hoped that the insights
achieved by this initial application will demonstrate the value of applying an SD approach to
this important public health concern. From a systems perspective, it is clear that
interventions focused on prescribing and dispensing behavior can have implications beyond
the medical aspects of the system, and it appears likely that a multifaceted approach
addressing licit as well as illicit use is warranted.
This initial effort is meant to stimulate the creation of additional models that address the
above limitations and that simulate policy interventions more directly tied to those currently
under discussion. However, the basic structure of the medical, trafficking, and nonmedical
sectors is expected to remain relevant as REMS are implemented and as the policy
landscape around this public health area continues to shift. The SD approach allows for
analysis of various points of intervention and for evaluation of alternative policies that aim
to ameliorate the negative outcomes associated with nonmedical use of pharmaceutical
opioids in the United States.
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Figure 1.

Escalation of unintentional drug-poisoning deaths in the United States from 1999 to 2008
Source. Warner (2011).

Wakeland et al.

Page 14

Figure 2.

Stock and flow diagram of the Medical Use Sector.
Note. Circled numbers correspond to bracketed notations in the text. Numbers in boxes
correspond to model parameters in Table 1.
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Figure 3.

Stock and flow diagram of the Trafficking Sector.
Note. Circled numbers correspond to bracketed notations in the text. Numbers in boxes
correspond to model parameters in Table 2.
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Figure 4.

Stock and flow diagram of the Nonmedical Use Sector.
Note. Circled numbers correspond to bracketed notations in the text. Numbers in boxes
correspond to model parameters in Table 3.
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Figure 5.

Model output versus reference behavior.
Note. From top left, clockwise: (a) total prescription opioid overdose deaths per year (Mean
Absolute Percentage Error [MAPE] 22%), (b) total nonmedical users of prescription opioids
(MAPE 9.1%), (c) total number of individuals initiating nonmedical opioid use per year
(MAPE 9.9%). For discussion on MAPE as a metric of model fitness, see Sterman (2000).
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Figure 6.

Effect of simulated interventions on total opioid overdose deaths, overdose deaths among
nonmedical users, and medical users.
Note. Baseline results (A) are shown for the historical period and evaluation period.
Intervention results (B, C, D) are shown only for the evaluation period.
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Table 1

References of Support for Model Parameters in the Medical Use Sector.
Parameters (Enumerated) and Reference Data

a

Value

Support

1, 2

All-cause mortality rate for those
receiving long-acting and shortacting opioids

0.012; 0.01

U.S. population mortality data, adjusted by panel
consensus

3

All-cause mortality rate for those
with abuse/addiction

0.015

U.S. population mortality data, adjusted by panel
consensus

4, 5

Average long- and short-acting
treatment duration (in years)

7; 5

Panel consensus

6

Base level of abuse potential for
opioids

1.3

Modeling team judgment, reviewed by Panel

7

Base rate for adding or switching
(to long-acting)

0.03

Extrapolation from outcome data: Verispan, LLC, SDI
Vector One®: National (VONA; see
Governale, 2008a)

8

a
Table function for base rate of
treatment

9

Base risk factor (degree tx
reduced in 1995 due to
perceived risk)

10

a
Table function for diagnosis rate
for chronic pain

11

Overdose mortality rate for
those abusing opioids

12

Overdose mortality rate for those
on long- and short-acting

14

Rate of addiction for those on
long- and short-acting

0.05

Meta-analyses (see Dunn et al., 2010; Højsted &
Sjøgren, 2007)

15

Rate of addiction for those on
short-acting

0.02

VISN16 data (South Central Veterans Affairs Health
Care Network; see Fishbain, Cole, Lewis, Rosomoff,
& Rosomoff, 2008)

16

a
Table function for short-acting
bias (as function of perceived
risk)

17

Tamper Resistance (baseline
value)

From 0.05 in 1995 to
0.23
in 2005
1.3

From 0.05 in 1995 to
0.15
in 2005
0.0015
0.0025; 0.00005

From (1,0) to (4,1)

1

Panel consensus, informed by Potter et al. (2001)

Modeling team judgment, reviewed by panel

Panel consensus, informed by WHO (World Health
Organization; see Gureje, Simon, & Von Korff,
2001)
Extrapolation from heroin research (see
Sullivan, 2007)
CONSORT study (Consortium to Study Opioid Risks
and Trends; see Potter et al., 2001)

Modeling team judgment, reviewed by panel

Policy variable (1 = status quo)

Physicians’ fear of overzealous
regulatory scrutiny when
prescribing opioids

Joranson et al. (2002)

Physicians’ decrease in opioid
prescribing after regulation

Wolfert et al. (2010)

Higher rate of abuse among longacting than short-acting opioids

Cicero, Suratt, Inciardi, and Munoz (2007)

Physicians’ tendency to exhibit
more caution in prescribing
long-acting than short-acting
opioids

Potter et al. (2001)

A Table Function is a series of XY coordinates representing a relationship (usually nonlinear) between two variables; initial and final values given
above.
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Table 2

References of Support for Model Parameters in the Trafficking Sector.
Parameter

Value

Support

1. Average number of dosage units per
opioid prescription

86

Extrapolation from dispensing data: Verispan, LLC, SDI Vector
One®: National (VONA; see Governale, 2008a, 2008b)

2. Average number of extra dosage units
taken per day among those with abuse or
addiction

1.5

Panel consensus

3. Fraction of those with abuse/addict who
engage in Dr shopping

0.5

Extrapolation from study results (Manchikanti et al., 2006)

4. Fraction of those with abuse/addict who
engage in forgery

0.4

Extrapolation from study results (Manchikanti et al., 2006)

5. Number of days of extra opioid usage
among those with abuse/addiction

50

Generalized from NSDUH data (National Survey on Drug
Use and Health 2002, 2003, & 2004; see Table 2.18B in
Colliver et al., 2006)

6. Profit multiplier

15

Modeling team judgment

From (0,0) to (2,1)

Modeling team judgment

a
7. Table function for the effect of perceived
risk on extra Rx obtained
a

A Table Function is a series of XY coordinates representing a relationship (usually nonlinear) between two variables; initial and final values given
above.
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Table 3

References of Support for Model Parameters in the Nonmedical Use Sector.
Parameters (Enumerated) and Reference
Data

Support

1

Base level of abuse potential of opioids

1.3

Panel Consensus

2

Fraction of demand met from chronic
pain trafficking

.25

Extrapolation from NSDUH 2006 results
(SAMHSA, 2007)

3

Fraction of low- frequency users who
switch to high- frequency

0.06

Extrapolation from MTF data (Monitoring the
Future; see Johnston, O’Malley, Bachman, & Schulenberg,
2007)
and results (Mack & Frances, 2003)

4, 5

Low- and high-frequency user all-cause
mortality rate

0.012; 0.02

Extrapolation from heroin research findings
(WHO; see Degenhard et al., 2004; Hser et al., 2001;
Rehm et al., 2005)

6, 7

Low- and high-frequency user cessation
rate

0.15; 0.08

Imputation from NSDUH data (National Survey
on Drug Use and Health, 2007; see
SAMHSA 2009)

8, 9

Number of days of nonmedical use
among low- and high-frequency users

30; 220

10

Number of dosage units taken per day of
nonmedical use

2

11, 12

Overdose mortality rate for low- and
high-frequency nonmedical users

13

Rate of initiation of nonmedical opioid
use

14

a
Table function for the impact of limited
accessibility on initiation and increasing
use

From (0,0) to (5,2)

15

a
Table function for the number of
individuals using illicit drugs excluding
marijuana and opioids

From 6.7M in 1995 to
8.6M in 2009

Calculated from NSDUH 2006 results, see
SAMHSA (2007)

16

a
Table function for US population ages 12
and older, as a function of time

From 211M in 1995 to
357M in 2007

Imputed from NSDUH data (National Survey on
Drug Use and Health 1995, 2002; see
SAMHSA, 1996, 2002)

Proportion of nonmedical users who
meet the DSM-IV criteria for abuse or
dependence
a

Value

0.0002; 0.002

0.006

12% to 14%

Extrapolation from NSDUH 2007 results
(Lee et al., 2010)
Modeling Team Judgment, reviewed by Panel
Extrapolation from research findings (Fischer et al., 2004;
Warner et al., 2009; Warner-Smith, Lynskey, Darke, &
Hall, 2000)
Imputed from National Drug Use and Health
Survey Data (NSDUH, 1995; see SAMHSA, 1996)
Modeling Team Judgment, reviewed by Panel

American Psychiatric Association (1994),
Colliver et al. (2006)

A Table Function is a series of XY coordinates representing a relationship (usually nonlinear) between two variables; initial and final values given
above.

